87 results about "PET-CT" patented technology

The invention relates generally to the field of cancer detection, diagnosis, subtyping, staging, prognosis, treatment and prevention. More particularly, the present invention relates to methods for the detection, and / or diagnosing and / or subtyping and / or staging of lung cancer in a patient. Based on a particular panel of biomarkers, the present invention provides methods to detect, diagnose at an early stage and / or differentiate small cell lung cancer (SCLC) from non-small cell lung cancer (NSCLC) and within NSCLC to differentiate between squamous cell carcinomas (SCC), adenocarcinomas (AC), within SCC to discriminate G2 and G3 stage and within lung cancer to differentiate for lung cancers with or without neuroendocrine origin. It further provides the use of said panel of biomarkers in monitoring disease progression in a patient, including both in vitro and in vivo imaging techniques. The in vitro imaging techniques typically include an immunoassay detecting protein or antibody of the biomarkers on a sample taken from said patient, e.g. serum or tissue sample. The in vivo imaging techniques typically include chest radiographs (X-rays), Computed Tomography (CT) imaging, spiral CT, Positron Emission Tomography (PET), PET-CT and scintigraphy for molecular imaging and diagnosis and to monitor disease progression and treatment response in patients. It is accordingly a further aspect to provide a kit to perform the aforementioned diagnosing and / or subtyping and / or staging assay and the imaging techniques, comprising reagents to determine the gene expression or protein level of the aforementioned panel of biomarkers for in vitro and in vivo applications.

The present invention belongs to the field of hospital nuclear medicine department technology, is suitable for overall lifecycle management of radiopharmaceutical used in treatment of a nuclear medicine department thyroid cancer, treatment of thyroid uptake function hyperfunction and PET-CT and SPECT imaging, and provides a management method of radiopharmaceutical comprising transport warehousingmanagement, medicine subpackaging management and drug utilization management. The management method of the radiopharmaceutical achieves whole-cycle radiopharmaceutical monitoring, facilitates enhancement of radiation source supervision, avoids loss of the radiation sources and ensures public safety, management of an intelligent standing book facilitates management of improving the radiopharmaceutical to allow the management of nuclear medicine department drugs to be more ordered, and achieve digitlization and intelligence, and receiving and issuing management of drugs by employing special medicine cabinets further avoids human vulnerability and ensures safety of the radiation sources.

The invention provides an indicating device and an indicating method for PET-CT(positrom emission tomograghy-computed tomography) rack mounting alignment. The indicating method includes the steps of respectively mounting a CT central indicating component and a PET central indicating component on a CT rack rotating part and a PET rack; by a laser of the CT central indicating component, emitting a laser beam to the PET rack for indicating a CT rotation center, regulating positions of front and back supporting points of the PET rack, aligning the laser beam to a first central indicator and a second central indicator on the PET central indicating component, thereby achieving alignment between the CT rotation center and the center position of a PET probe. The indicating device is simple in structure and convenient to regulate; by the indicating device and the indicating method, influence from processing and mounting error of the CT central component can be eliminated, alignment precision is high, and the requirement on the mounting coaxiality of the PET probe center and the CT rotation center is guaranteed.